We investigate the association between psychological stress and breast cancer and, as oestrogen may provide a common mechanism, the association between stress and prostate cancer. A prospective study of 991 women and 5743 men employed in Scotland in the 1970s provided data. Risk exposure was measured by questionnaire and physical examination, routine data collection provided cancer outcomes over the subsequent 30 years. There was weak evidence of elevated incidences in those reporting moderate (breast cancer: hazard ratio [HR] 2.16, 95% CI 1.00-4.71; prostate cancer: HR 1.65, 95% CI 1.20-2.27) and high stress (breast cancer: HR 1.92, 95% CI 0.81-4.55; prostate cancer: HR 1.35, 95% CI 0.87-2.10) compared to those reporting low stress. These estimates are adjusted for socioeconomic circumstances and health-related behaviours. With no dose-response relationship and no established mechanism linking stress with breast and prostate cancer, confounding is the parsimonious explanation of these findings.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2007.01.027DOI Listing

Publication Analysis

Top Keywords

prostate cancer
20
breast cancer
16
stress breast
12
cancer
10
cancer prospective
8
stress
6
breast
5
prostate
5
role self-reported
4
self-reported stress
4

Similar Publications

Reply to: Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.

J Clin Oncol

January 2025

Fred Saad, MD, University of Montreal, Montreal, QC, Canada; Egils Vjaters, MD, P. Stradinš Clinical University Hospital, Riga, Latvia; Isabella Testa, MD, Bayer S.p.A, Milan, Italy; and Kunhi Parambath Haresh, MD, All India Institute of Medical Sciences, New Delhi, India.

View Article and Find Full Text PDF

Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.

J Clin Oncol

January 2025

Abhenil Mittal, MD, DM, MBBS and Geordie Linford, MD, MSc, BSc, Department of Oncology, Northeast Cancer Center, Health Sciences North, Sudbury, ON, Canada, Division of Clinical Sciences, Northern Ontario School of Medicine, ON, Canada; and Bishal Gyawali, MD, PhD, FASCO, Department of Oncology, Queen's University, Kingston, ON, Canada, Department of Public Health Sciences, Queen's University, Kingston, ON, Canada, Division of Cancer Care and Epidemiology, Queen's University, Kingston, ON, Canada.

View Article and Find Full Text PDF

Background: Prostate cancer remains the most frequent cancer among men, representing a significant health burden. Despite its high morbidity and mortality rates, the etiology of prostate cancer remains relatively unknown, with only non-modifiable established risk factors. Chronic inflammation has emerged as a potential factor in prostate carcinogenesis.

View Article and Find Full Text PDF

Precise surgical resection of prostate cancer (PCa) is a significant clinical challenge due to the impact of positive surgical margins on postoperative outcomes. Fluorescence-guided surgery (FGS) enables real-time tumor visualization using fluorescent probes. In this study, we synthesized and evaluated an indocyanine green (ICG)-based PSMA-targeted near-infrared probe, , for intraoperative imaging of PCa lesions.

View Article and Find Full Text PDF

Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.

J Zhejiang Univ Sci B

January 2025

Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.

Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!